

Hemophilia - Pipeline Assessment and Market Forecasts to 2017

Hemophilia - Pipeline Assessment and Market Forecasts to 2017

GlobalData

Date: December 1, 2010

Pages: 40

Price: US\$ 2,000.00

ID: HBD5995EF50EN

Hemophilia - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Hemophilia - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's analysis suggests that the global hemophilia therapeutics market was valued at \$6.5 billion in 2009. It is expected to increase at a Compound Annual Growth Rate (CAGR) of 5.8% from \$6.5 billion in 2009 to \$10.4 billion by 2017. This slow growth of 5.8% is primarily attributed to a low diagnosis rate and the high cost of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX, a clotting factor from Pfizer Inc.

Scope

The report provides information on the key drivers and challenges of the hemophilia market. Its scope includes:

- Annualized global hemophilia market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include Recombinant coagulation factors (VIIa, VIII, IX), plasma derived coagulation factors, thrombin generation, gene therapy, stem cell therapy, fast acting recombinant Factor VIIa, long acting Factor VIIa and monoclonal antibodies.
- Analysis of the current and future competition in the global hemophilia market. Key market players covered are Baxter Healthcare Corporation, Novo Nordisk, Bayer Healthcare Pharmaceuticals, Pfizer Inc, PTC Therapeutics Inc., Reclon N.V., Ipsen S.A and Biogen Idec Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global hemophilia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global hemophilia market landscape? – Identify, understand and capitalize.

Table of Content

1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2 HEMOPHILIA THERAPEUTICS: INTRODUCTION

- 2.1 Disease Overview
- 2.2 Diagnosis
- 2.3 Treatment and Management of Hemophilia
 - 2.3.1 Factor Concentrates
 - 2.3.2 Recombinant Coagulation Factors
 - 2.3.3 Cryoprecipitate
 - 2.3.4 Fresh Plasma
 - 2.3.5 Whole Blood
- 2.4 Inhibitors
- 2.5 Acquired Hemophilia
 - 2.5.1 Treatment of Acquired Hemophilia
- 2.6 Epidemiology
- 2.7 GlobalData Pipeline Report Guidance

3 HEMOPHILIA THERAPEUTICS: MARKET CHARACTERIZATION

- 3.1 Hemophilia Therapeutics Market Size
- 3.2 Hemophilia Therapeutics Market Forecast and CAGR
- 3.3 Drivers and Barriers for the Hemophilia Therapeutics Market
 - 3.3.1 Drivers for the Hemophilia Therapeutics Market
 - 3.3.2 Barriers for the Hemophilia Therapeutics Market
- 3.4 Opportunity and Unmet Need
- 3.5 Key Takeaway

4 HEMOPHILIA THERAPEUTICS MARKET: COMPETITIVE ASSESSMENT

- 4.1 Overview
- 4.2 Strategic Competitor Assessment

4.3 Product Profile for the Major Marketed Products in the Hemophilia Therapeutics Market

- 4.3.1 NovoSeven (Novo Nordisk)
 - 4.3.2 Advate (Baxter International)
 - 4.3.3 Kogenate FS (Bayer Healthcare)
 - 4.3.4 XYNTHA (Pfizer)
 - 4.3.5 BeneFIX (Pfizer)
 - 4.3.6 FEIBA-VH (Baxter International)
 - 4.3.7 Octaplex (Octapharma)
- #### 4.4 Key Takeaway

5 HEMOPHILIA THERAPEUTICS MARKET: PIPELINE ASSESSMENT

- 5.1 Overview
- 5.2 Strategic Pipeline Assessment
 - 5.2.1 Technology Trends Analytic Framework
- 5.3 Molecule Profile for Promising Drugs under Clinical Development
 - 5.3.1 Ataluren (PTC124)
 - 5.3.2 NecLip-rFVIIa (LongSeven)
 - 5.3.3 NecLip-pdFVIII (LongAte)
- 5.4 Hemophilia Therapeutics Market – Clinical Pipeline by Mechanism of Action
 - 5.4.1 Hemophilia Therapeutics Pipeline – Pipeline by Clinical Phase of Development
 - 5.4.2 Hemophilia Therapeutics, Phase III Clinical Pipeline
 - 5.4.3 Hemophilia Therapeutics – Phase II Clinical Pipeline
 - 5.4.4 Hemophilia Therapeutics, Phase I Clinical Pipeline
 - 5.4.5 Hemophilia Therapeutics, Discovery and Preclinical Pipeline
- 5.5 Key Takeaway

6 HEMOPHILIA THERAPEUTICS MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION

7 HEMOPHILIA THERAPEUTICS MARKET: FUTURE PLAYERS IN THE HEMOPHILIA THERAPEUTICS MARKET

- 7.1 Introduction
- 7.2 Bayer Healthcare (Bayer Schering Pharma AG)
 - 7.2.2 Hemophilia Portfolio
- 7.3 PTC Therapeutics
 - 7.3.1 Overview
 - 7.3.2 Hemophilia Portfolio
- 7.4 Hemophilia Pipeline Portfolio
 - 7.4.1 Ataluren (PTC124)
- 7.5 Novo Nordisk
 - 7.5.1 Overview
 - 7.5.2 Hemophilia Portfolio
- 7.6 Baxter International
 - 7.6.1 Overview
 - 7.6.2 Financial Performance
 - 7.6.3 Hemophilia Portfolio
- 7.7 Recoly N.V.
 - 7.7.1 Overview
 - 7.7.2 Hemophilia Portfolio
- 7.8 Hemophilia Pipeline Portfolio
 - 7.8.1 NecLip-rFVIIa (LongSeven)

8 HEMOPHILIA THERAPEUTICS MARKET: APPENDIX

- 8.1 Definitions
- 8.2 Acronyms
- 8.3 Research Methodology
 - 8.3.1 Coverage
 - 8.3.2 Secondary Research
 - 8.3.3 Forecasting
 - 8.3.4 Primary Research
 - 8.3.5 Expert Panel Validation
- 8.4 Contact Us
- 8.5 Disclaimer
- 8.6 Sources

LIST OF TABLES

- Table 1: Bleeding Manifestations in Hemophilia
- Table 2: Hemophilia Bleeding Sites
- Table 3: Consumption Breakdown of Factor Concentrates
- Table 4: Patients Diagnosed in 2008
- Table 5: Hemophilia Therapeutics Market, Global, Revenues (\$bn), 2001-2009
- Table 6: Hemophilia Therapeutics Market, Global, Revenue (\$bn), 2009-2017
- Table 7: Hemophilia Therapeutics, Filed and Phase III Clinical Pipeline, December 15, 2010
- Table 8: Hemophilia Therapeutics, Phase II Clinical Pipeline, December 15, 2010
- Table 9: Hemophilia Therapeutics – Phase I Clinical Pipeline, December 15, 2010
- Table 10: Hemophilia Therapeutics, Discovery and Preclinical Pipeline, December 15, 2010
- Table 11: Bayer Healthcare, Hemophilia Pipeline Products, 2010
- Table 12: PTC Therapeutics, Inc., Hemophilia Pipeline Products, 2010
- Table 13: Novo Nordisk, Hemophilia Pipeline Products, 2010
- Table 14: Baxter International, Hemophilia Pipeline Products, 2010
- Table 15: Recoly N.V., Hemophilia Pipeline Products, 2010

LIST OF FIGURES

- Figure 1: Key Aspects of the Management of Hemophilia
- Figure 2: Hemophilia Therapeutics Market, Global, Revenues (\$bn), 2001-2009
- Figure 3: Hemophilia Therapeutics Market, Global, Revenue (\$bn), 2009-2017
- Figure 4: Opportunity and Unmet Need in the Hemophilia Therapeutics Market, 2010
- Figure 5: Strategic Competitor Assessment of the Major Marketed Products for Hemophilia, 2010
- Figure 6: Technology Trends Analytic Framework of the Hemophilia Pipeline, December 15, 2010
- Figure 7: Technology Trends Analytic Framework of the Hemophilia Pipeline, Description, 2010
- Figure 8: Hemophilia Therapeutics, Global, Clinical Pipeline by Mechanism of Action, 2010
- Figure 9: Hemophilia Therapeutics Pipeline by Phase of Clinical Development, December 15, 2010
- Figure 10: Implications for Future Market Competition in the Hemophilia Therapeutics Market, 2010
- Figure 11: Hemophilia Therapeutics Market, Clinical Pipeline by Company December 15, 2010
- Figure 12: GlobalData Market Forecasting Model

COMPANIES MENTIONED

- Bayer Healthcare (Bayer Schering Pharma AG)
- PTC Therapeutics
- Hemophilia Pipeline Portfolio
- Novo Nordisk
- Baxter International
- Recoly N.V.
- Hemophilia Pipeline Portfolio

I would like to order:

Product name: Hemophilia - Pipeline Assessment and Market Forecasts to 2017
Product link: <http://marketpublishers.com/r/HBD5995EF50EN.html>
Product ID: HBD5995EF50EN
Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <http://marketpublishers.com/r/HBD5995EF50EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at http://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**

